Amyris (AMRS) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
AMYRIS, INC. REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
May 10, 2022 8:00 AM EDTRecord consumer revenue of $34.6 million increased 121% compared to Q1 2021Barra Bonita commissioning on track to commence ingredients production in Q2
EMERYVILLE, Calif., May 10, 2022 /PRNewswire/ --Â Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for the first quarter ended March 31, 2022.
"We continued to advance our growth roadmap, delivering 75% core revenue growth and growing consumer... More
